Fatima Elamin
Endocrinology, Diabetes & Metabolism · Columbia, MDNPI 1477935575
Payments from drug & device makers
Across 17 payments — averaging $26.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$126
- Novo Nordisk$51
- Lilly USA, LLC$51
- AstraZeneca$39
- Insulet Corporation$29
- Globus Medical$28
- plus $119 from 5 others
What the payments were for
- Food & beverage$31772%
- Education$12628%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 1 | $126 |
| Novo Nordisk | 2 | $51 |
| Lilly USA, LLC | 3 | $51 |
| AstraZeneca | 3 | $39 |
| Insulet Corporation | 1 | $29 |
| Globus Medical | 1 | $28 |
| Corcept Therapeutics | 1 | $28 |
| BD | 2 | $26 |
| Radius Health, Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $24 |
| Novartis | 1 | $15 |
How this compares
$443 in reported general payments places this provider in the 25th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humalog Kwikpen U-100Insulin Lispro | 27 | $5,634 |
| Insulin Glargine-Yfgn | 38 | $4,316 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,106 |
| Methimazole | 28 | $591 |
| Levothyroxine Sodium | 29 | $456 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 21 | $444 |
| Metformin Hcl ErMetformin Hcl | 16 | $133 |
| Atorvastatin Calcium | 14 | $78 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Columbia
- Jean ParkBaltimore$3.7M
- Michael DempseyRockville$2.7M
- Ilias SpanakisBaltimore$2.6M
- Helena RodbardRockville$2.4M
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Romeu AzevedoCamp Springs$1.1M
- Nicholas ArgentoLaurel$1.1M
- Philip LevinBaltimore$702K
- David BrownRockville$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.